Filing Details

Accession Number:
0001209191-22-004143
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-20 17:55:40
Reporting Period:
2022-01-19
Accepted Time:
2022-01-20 17:55:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1706431 Vir Biotechnology Inc. VIR Biological Products, (No Disgnostic Substances) (2836) 812730369
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1787370 Phillip Pang C/O Vir Biotechnology, Inc.
499 Illinois Street, Suite 500
San Francisco CA 94158
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-19 5,000 $1.53 97,777 No 4 M Direct
Common Stock Disposition 2022-01-19 2,458 $34.59 95,319 No 4 S Direct
Common Stock Disposition 2022-01-19 2,542 $35.52 92,777 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-01-19 5,000 $0.00 5,000 $1.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
62,591 2028-04-27 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.12 to $35.06 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.13 to $35.865 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.